{"entity":{"id":"tri-611","kind":"drug","name":"TRI-611","aka":[],"tldr":"TRI-611 is an experimental protein degrader from TRIANA Biomedicines in phase 2 trials for non-small-cell lung cancer, aimed at ALK.","summary":"TRI-611 is a protein degrader developed by TRIANA Biomedicines. Its target is ALK (the sponsor names ALK). The sponsor states: TRI-611 is an oral, brain-penetrant molecular glue degrader that brings ALK fusion proteins and cereblon together through a mechanism independent of the kinase active site, driving degradation of ALK fusion proteins in ALK-positive NSCLC. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT07491497, plans to enrol 160 participants with primary completion expected 2029-05-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of TRI-611","url":"https://clinicaltrials.gov/search?intr=TRI-611"},{"label":"Sponsor pipeline page","url":"https://www.trianabio.com/pipeline"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["alk"],"drugs":[],"companies":["triana-biomedicines"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07491497"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"protein degrader","mechanism":"TRI-611 is an oral, brain-penetrant molecular glue degrader that brings ALK fusion proteins and cereblon together through a mechanism independent of the kinase active site, driving degradation of ALK fusion proteins in ALK-positive NSCLC.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tri-611/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"alk","kind":"target","name":"ALK","route":"/targets/alk/"}],"company":[{"id":"triana-biomedicines","kind":"company","name":"Triana Biomedicines","route":"/companies/triana-biomedicines/"}],"trial":[{"id":"nct07491497","kind":"trial","name":"A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC","route":"/trials/nct07491497/"}]}}